JOP20220187A1 - لقاح فيروس الورم الحليمي البشري (hpv) - Google Patents

لقاح فيروس الورم الحليمي البشري (hpv)

Info

Publication number
JOP20220187A1
JOP20220187A1 JOP/2022/0187A JOP20220187A JOP20220187A1 JO P20220187 A1 JOP20220187 A1 JO P20220187A1 JO P20220187 A JOP20220187 A JO P20220187A JO P20220187 A1 JOP20220187 A1 JO P20220187A1
Authority
JO
Jordan
Prior art keywords
hpv
vaccine
papilloma virus
human papilloma
human papillomavirus
Prior art date
Application number
JOP/2022/0187A
Other languages
English (en)
Inventor
S Espeseth Amy
J Bett Andrew
Fu Tong-Ming
P Bilello John
E Gindy Marian
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of JOP20220187A1 publication Critical patent/JOP20220187A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

يوفر الكشف الحالي، من بين أمور أخرى، تركيبة صيدلانية تتضمن مادة مساعدة دهنية نانوية الجسيمات ومضاد فيروس ورم حليمي بشري (HPV) يشتمل على جسيمات شبيهة بفيروس HPV (VLPs) لنوع واحد على الأقل من فيروس الورم الحليمي البشري (HPV) مختار من المجموعة التي تتكون من أنواع HPV: 6، 11، 16، 18، 26، 31، 33، 35، 39، 45، 51، 52، 53، 55، 56، 58، 59، 66، 68، 73، و82. الشكل 1أ
JOP/2022/0187A 2020-02-14 2021-02-09 لقاح فيروس الورم الحليمي البشري (hpv) JOP20220187A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976673P 2020-02-14 2020-02-14
PCT/US2021/017157 WO2021163002A1 (en) 2020-02-14 2021-02-09 Hpv vaccine

Publications (1)

Publication Number Publication Date
JOP20220187A1 true JOP20220187A1 (ar) 2023-01-30

Family

ID=74853762

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0187A JOP20220187A1 (ar) 2020-02-14 2021-02-09 لقاح فيروس الورم الحليمي البشري (hpv)

Country Status (21)

Country Link
US (3) US11638754B2 (ar)
EP (1) EP4103227A1 (ar)
JP (1) JP2023516904A (ar)
KR (1) KR20220140901A (ar)
CN (1) CN115103687A (ar)
AR (1) AR121292A1 (ar)
AU (1) AU2021219652A1 (ar)
BR (1) BR112022015313A2 (ar)
CA (1) CA3166256A1 (ar)
CL (1) CL2022002167A1 (ar)
CO (1) CO2022011392A2 (ar)
CR (1) CR20220395A (ar)
DO (1) DOP2022000168A (ar)
EC (1) ECSP22063122A (ar)
IL (1) IL295234A (ar)
JO (1) JOP20220187A1 (ar)
MX (1) MX2022009964A (ar)
PE (1) PE20230493A1 (ar)
PH (1) PH12022552075A1 (ar)
TW (1) TW202140069A (ar)
WO (1) WO2021163002A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103227A1 (en) * 2020-02-14 2022-12-21 Merck Sharp & Dohme LLC Hpv vaccine
CN118019547A (zh) * 2021-08-19 2024-05-10 默沙东有限责任公司 热稳定脂质纳米粒子及其使用方法
CN115850686B (zh) * 2021-09-27 2026-01-30 广州谷森制药有限公司 新型氘代聚乙二醇脂质化合物
US11951177B2 (en) * 2022-03-23 2024-04-09 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE122007000093I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
DE602005020913D1 (de) 2004-03-24 2010-06-10 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
KR20080005585A (ko) 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20100055168A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20100076055A1 (en) 2008-04-16 2010-03-25 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
US20100063135A1 (en) 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010030730A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
EP2444954A1 (en) 2009-06-17 2012-04-25 Sharp Kabushiki Kaisha Display driving circuit, display device and display driving method
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
WO2012040184A2 (en) 2010-09-20 2012-03-29 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
AU2012272788B2 (en) 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
EP3556353A3 (en) * 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CA3002819A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
EP4103227A1 (en) * 2020-02-14 2022-12-21 Merck Sharp & Dohme LLC Hpv vaccine

Also Published As

Publication number Publication date
US20230123584A1 (en) 2023-04-20
EP4103227A1 (en) 2022-12-21
MX2022009964A (es) 2022-09-19
PE20230493A1 (es) 2023-03-23
CA3166256A1 (en) 2021-08-19
ECSP22063122A (es) 2022-11-30
TW202140069A (zh) 2021-11-01
CR20220395A (es) 2022-10-27
PH12022552075A1 (en) 2024-02-12
US11638754B2 (en) 2023-05-02
AR121292A1 (es) 2022-05-04
WO2021163002A1 (en) 2021-08-19
CN115103687A (zh) 2022-09-23
AU2021219652A1 (en) 2022-08-18
IL295234A (en) 2022-10-01
CO2022011392A2 (es) 2022-08-19
BR112022015313A2 (pt) 2022-09-27
US20210252138A1 (en) 2021-08-19
JP2023516904A (ja) 2023-04-21
KR20220140901A (ko) 2022-10-18
CL2022002167A1 (es) 2023-02-03
DOP2022000168A (es) 2022-09-30
US20230270850A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
WO2020163719A3 (en) Nanoparticle-based influenza virus vaccines and uses thereof
JP2016155867A5 (ar)
SG131116A1 (en) Functional influenza virus-like particles (vlps)
WO2017136575A8 (en) Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
DK1294892T3 (da) Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EA201171033A1 (ru) Вакцины против гриппа со сниженным количеством сквалена
ZA202201571B (en) Polyvalent immunogenicity composition for human papillomavirus
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
EA201170264A1 (ru) Вакцина против hpv
CY1113830T1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
WO2022261297A3 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX2024002144A (es) Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
ATE474596T1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
JOP20250304A1 (ar) تركيبات مساعدة في صورة مستحلب نانوي للقاحات فيروس الورم الحليمي البشري
WO2021021753A3 (en) A porcine circovirus type 2 (pcv2) vaccine
EP1576143A4 (en) VIRUSELY PARTICLES, METHOD OF PREPARATION AND IMMUNOGENIC COMPOSITIONS
WO2021142256A3 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
EA200702077A1 (ru) Вакцина
MY192396A (en) An influenza a vaccine
AR037908A1 (es) Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus